Factors Affecting Best-Tolerated Dose of Pirfenidone in Patients with Fibrosing Interstitial Lung Disease

The aim of the study was to examine the best-tolerated dose of pirfenidone, the adverse effects profile, and potential factors other than drug dose influencing the tolerability of pirfenidone in patients with fibrosing interstitial lung diseases (ILDs). We performed an observational retrospective st...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical medicine 2023-10, Vol.12 (20), p.6513
Main Authors: Mandovra, Neha P, Vaidya, Preyas J, Shah, Ria S, Nighojkar, Aishwarya S, Chavhan, Vinod B, Lohiya, Ayush, Leuppi, Joerg D, Leuppi-Taegtmeyer, Anne, Chhajed, Prashant N
Format: Article
Language:English
Subjects:
Clinical medicine
Drug dosages
Drug therapy
Drug tolerance
Growth factors
Lung diseases
Lung diseases, Interstitial
Meals
Patient outcomes
Patients
Pharmaceutical research
Pulmonary fibrosis
Risk factors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The aim of the study was to examine the best-tolerated dose of pirfenidone, the adverse effects profile, and potential factors other than drug dose influencing the tolerability of pirfenidone in patients with fibrosing interstitial lung diseases (ILDs). We performed an observational retrospective study of 113 patients with IPF and other fibrosing ILDs treated with pirfenidone. Baseline liver function tests (LFTs) and dose escalation of pirfenidone were recorded for all patients. The best-tolerated dose was continued if the patient did not tolerate full dose (2400 mg) despite repeated dose escalation attempts. Potential risk factors such as age, height, weight, body mass index (BMI), body surface area (BSA), gender, smoking, and presence of comorbidities were analyzed between 3 groups of best-tolerated pirfenidone doses: 2400 mg/day vs.
ISSN:2077-0383
2077-0383
DOI:10.3390/jcm12206513